The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future ...
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...
Three decades ago, a scientist at the University of Texas named Bruce Beutler asked the U.S. government to grant him a patent for a new invention. Beutler, who would later win the Nobel Prize for his ...
In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...
The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech ...
Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, ...
While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...
The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and ...
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why ...
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...
Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results